Company profile
Oculis SA
Oculis S.A. is a biopharmaceutical company focused on developing transformative topical ophthalmic treatments using its innovative formulation technologies to improve the sight and lives of patients. Oculis' novel topical (eye drop) treatments are non-invasive and represent an unprecedented technical advance for patients with retinal and front-of-the-eye diseases. The Company's leading clinical candidates are: - OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone based on Oculis' proprietary Solubilizing Nanoparticle (SNP) technology. - OCS-02 is a novel topical anti-TNF alpha antibody. In addition, Oculis' formulation discovery focus and capabilities are enabling the development of topical drugs targeting sight-threatening diseases.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
